Guidance Issued for Genetic Testing in Prostate Cancer
Germline testing advised for metastatic disease, family history suggestive of hereditary disease
Prostate And Other Male Cancers
Spironolactone Use Associated With Reduced Prostate Cancer Risk
Men who had ever used spironolactone had decreased odds of prostate cancer compared with never-users, according to a study.
New Guideline Issued for Managing Advanced Prostate Cancer
Three major medical organizations have issued recommendations for the diagnosis and treatment of advanced prostate cancer, including metastatic hormone-sensitive disease and nonmetastatic and metastatic castration-resistant disease.
ASCO: Relugolix Superior to Leuprolide in Advanced Prostate Cancer
And, enzalutamide improves median overall survival in nonmetastatic, castration-resistant prostate cancer.
Lynparza Approved for Metastatic Castration-Resistant Prostate Cancer
The FDA has approved Lynparza® (olaparib; AstraZeneca and Merck) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
Rubraca Approved for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutations
The FDA has granted accelerated approval to Rubraca for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
Statin Use May Reduce Mortality in High-Risk Prostate Cancer
Statin use alone or in combination with metformin tied to lower all-cause, prostate cancer mortality.
2019 New Drug Approvals: Hematology/Oncology
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
FDA Approves Xtandi for Metastatic Castration-Sensitive Prostate Cancer
The primary end point was radiographic progression-free survival (rPFS), defined as the time from randomization to radiographic disease progression at any time or death within 24 weeks after drug discontinuation.
Large Verdict Awarded to Patient After Unnecessary Surgery
The examination of the removed prostate revealed no cancer, it was subsequently discovered that the original tissue sample had been mixed up with that of a patient who had prostate cancer.
